Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: Results from the ABRAB study

Table 1 Baseline demographic and disease characteristics*

	Group A (n = 49) (MTX treatment) % v. mean (SD)	Group B (n = 35) (anti-TNF + MTX treatment) % v. mean (SD)
Age, (mean ± S.D.)	60.1 (13.7)	54.7 (15)
Women, n (%)	42 (85.7%)	28 (80%)
Disease duration, (month)	7.9 (2)	8.5 (1.2)
IgM RF positive, n (%)	34 (69.4%)	22 (62.9%)
Anti-CCP positive, n (%)	37 (75.5%)	26 (74.3%)
DAS28ESR , mean ± S.D.	6.1 (0.9)	6.4 (0.9)
CDAI, mean ± S.D.	36.2 (11.5)	33.6 (12.7)
Tender joint count, mean ± S.D.	13.1 (6.5)	14 (7.2)
Swollen joint count, mean ± S.D.	7.5 (5.9)	9.4 (5.2)
Patient global assessment (VAS 0–100), mean ± S.D.	65 (17.9)	64.3 (18.3)
ESR, mean ± S.D.	43.7 (22.4)	46.9 (33.5)
CRP, mean ± S.D.	27.5 (28.4)	40.3 (46.9)
HAQ-DI (0–3), mean ± S.D.	1.4 (0.7)	1.6 (0.7)

*There were no statistically significant differences in any demographic or baseline characteristics between the groups, by Mann–Whitney test for continuous variables and chi-square test for dichotomous variables; statistical significance was set as p < 0.05.
(RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated protein, DAS28ESR: disease activity score based on the erythrocyte sedimentation rate, CDAI: clinical disease activity index, VAS: visual analogue scale, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, HAQ-DI: Health Assessment Questionnaire - Disability Index, vdHS: van der Heijde modified Sharp score).